481681-02-1

Basic information

• Product Name: 4-FLUORO-3-(HYDROXYMETHYL)BENZENEBORONIC ACID
• Synonyms: 4-FLUORO-3-(HYDROXYMETHYL)BENZENEBORONIC ACID;4-FLUORO-3-(HYDROXYMETHYL)PHENYLBORONIC ACID;4-Fluoro-3-(hydroxymethyl)benzeneboronic acid 98%;4-Fluoro-3-(hydroxymethyl)benzeneboronicacid98%;[4-Fluoro-3-(hydroxymethyl)phenyl]boronic acid ,98%;[4-fluoro-3-(hydroxymethyl)phenyl]boronic acid(SALTDATA: FREE);4-Fluoro-3-(hydroxymethyl)phenylboronic Acid (contains varying amounts of Anhydride);4-Fluoro-3-(hydroxymethyl)phenyl
• CAS NO: 481681-02-1
• Molecular Formula: C₇H₈BFO₃
• Molecular Weight: 169.95
• Product Categories: blocks;BoronicAcids
• Mol File: 481681-02-1.mol

Chemical Properties

• Melting Point: 124-126
• Boiling Point: 365.782 °C at 760 mmHg
• Flash Point: 175.019 °C
• Appearance: /
• Density: 1.353 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.542
• Storage Temp.: Keep Cold
• PKA: 8.39±0.10(Predicted)
• CAS DataBase Reference: 4-FLUORO-3-(HYDROXYMETHYL)BENZENEBORONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-FLUORO-3-(HYDROXYMETHYL)BENZENEBORONIC ACID(481681-02-1)
• EPA Substance Registry System: 4-FLUORO-3-(HYDROXYMETHYL)BENZENEBORONIC ACID(481681-02-1)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 481681-02-1(Hazardous Substances Data)

Usage

Uses

suzuki reaction

InChI:InChI=1/C7H8BFO3/c9-7-2-1-6(8(11)12)3-5(7)4-10/h1-3,10-12H,4H2

Upstream product

• 99725-13-0 (5-bromo-2-fluorophenyl)methanol 
• 374538-01-9 (4-fluoro-3-formylphenyl)boronic acid 
• 5419-55-6 Triisopropyl borate 
• 93777-26-5 5-bromo-2-fluorobenzaldehyde 

Downstream Products

• 1093064-47-1 3-(4-fluoro-3-hydroxymethylphenyl)-5-nitro-1-trityl-1H-indazole 
• 1312603-21-6 [5-(2-chloro-pyrimidin-4-yl)-2-fluorophenyl]methanol 
• 1093064-48-2 3-(4-fluoro-3-(2-methoxyxymethyl)-phenyl)-5-nitro-1-trityl-1H-indazole 
• 1093064-49-3 3-[4-fluoro-3-(2-methoxymethyl)-phenyl]-1-trityl-1H-indazol-5-ylamine 
• 1312603-66-9 [4-(3-allyloxymethyl-4-fluorophenyl)-pyrimidin-2-yl]-[3-allyloxymethyl-4-(2-pyrrolidin-1-yl-ethoxy)phenyl]amine 
• 1312603-28-3 4-(3-allyloxymethyl-4-fluoro-phenyl)-2-chloropyrimidine 

Relevant articles and documents

PYRIMIDINYL GROUP-CONTAINING TRICYCLIC COMPOUND SERVING AS C-MET INHIBITOR

Disclosed are a pyrimidinyl group-containing tricyclic compound and applications thereof in preparing a cancer-treating medicament. Specifically disclosed are a compound as represented by formula (I), a pharmaceutically acceptable salt of same, or an isomer thereof.

Controlled release system based on mesoporous silica nanoparticles and preparation method thereof

The invention relates to a meso-porous silicon oxide nanoparticle-based controlled release system and a preparation method thereof, and concretely relates to a meso-porous silicon oxide-based nanoparticle for controlled release, a controlled release system containing the nanoparticle, and a preparation method and a kit of the nanoparticle. The nanoparticle contains a phenyl borate functionalized meso-porous silicon oxide nanoparticle and a surface functionalized nanoparticle hole plugging agent which can be combined with phenyl borate. When no substrate exists, a nanometer silicon oxide system in the invention can realize zero early release; and after the substrate is added, a meso-porous tunnel plugged by the nanoparticle is opened in order to realize controlled release of a content. The method has the advantages of simple material synthesis, adjustable composition, and realization of responses to different substrates and different concentrations.

PHOSPHONATE CONJUGATES AND USES THEREOF

Phosphonate conjugates, preferably, bisphosphonate conjugates; methods of inhibiting Ron receptor tyrosine kinase and methods of treatment of bone destruction due to cancer or other conditions utilizing the provided phosphonate conjugates.

8-(BIARYL) QUINOLINE PDE4 INHIBITORS

8-(biaryl) quinolines wherein the bi-aryl group at the 8-position is in a meta relationship to the quinoline group, are PDE4 inhibitors useful in the treatment of asthma, chronic bronchitis, chronic obstructive pulmonary disease, eosinophilic granuloma, psoriasis and other benign or malignant proliferative skin diseases, endotoxic shock, laminitis in horses, colic in horses, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, inflammatory arthritis, chronic glomerulonephritis, atopic dermatitis, urticaria, adult respiratory distress syndrome, chronic obstructive pulmonary disease in animals, diabetes insipidus, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, arterial restenosis, ortherosclerosis, atherosclerosis, neurogenic inflammation, pain, cough, rheumatoid arthritis, ankylosing spondylitis, transplant rejection, graft versus host disease, hypersecretion of gastric acid, bacterial, fungal induced sepsis, viral induced sepsis, fungal induced septic shock, viral induced septic shock, inflammation-mediated chronic tissue degeneration, cytokine-mediated chronic tissue degeneration, osteoarthritis, cancer, cachexia, muscle wasting, depression, memory impairment, tumour growth, or cancerous invasion of normal tissues.In another aspect, the present invention is directed to a method of enhancing cognition in a healthy subject comprising administering a safe cognition enhancing amount of phosphodiesterase-4 inhibitor. In particular, this invention is directed to a method of enhancing memory, learning, retention, recall, awareness and judgement in health subjects comprising administering a safe and cognition enhancing amount of a phosphodiesterase-4 inhibitor.